Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

One arm, two shots: study tests combo COVID-Flu vaccination

NCT ID NCT06831786

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study involved 36 healthy Thai adults to see if getting a COVID-19 booster and flu vaccine together is as effective and safe as getting them separately. Researchers measured immune responses and side effects over one month. The goal was to gather information to potentially simplify future vaccination schedules.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

36 people

The number who actually took part.

Started

Mar 2024

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Thai adults aged 18-60 years, who have vaccinated COVID-19 and influenza vaccine more than 6 months. * The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the 1-month follow-up of the study. * Individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator and meet the requirements of immunization. * The subject can provide with informed consent and sign informed consent form (ICF). Exclusion Criteria: * Have history of influenza or COVID-19 infection within 6 months. * Have the medical history or family history of convulsion, epilepsy, encephalopathy, and psychosis. * Be allergic to any component of the research vaccines or used to have a history of hypersensitivity or serious reactions to vaccination. * History of Guillain-Barré syndrome. * Women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan within six months of after baseline period. * Have infectious diseases, including HIV and SARS-CoV-2 infection or any symptom of common cold. * Have history of SARS-CoV-2 infection less than 6 months. * Having severe chronic diseases or condition in progress cannot be controlled. For example, poor controlled DM and uncontrolled HT. * Have the history of urticaria 1 year before receiving the investigational vaccine. * Have known underlying diseases of thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection). * Having needle sickness. * Have the history of immunosuppressive therapy, cytotoxic therapy, or systemic corticosteroids. * Have received blood products within 4 months before injection of investigational vaccines. * Under anti-tuberculosis treatment. * Not be able to follow the protocol, or not be able to understand the informed consent according to the researcher's judgment, due to various medical, psychological, social, or other conditions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Faculty of Medicine, Prince of Songkla University

    Songkhla, 90110, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.